Overview

Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study was intended to assess the safety, efficacy, and response to treatment using the American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) and to investigate a potential biomarker profile in adult patients with established rheumatoid arthritis
Phase:
Phase 2
Details
Lead Sponsor:
Novartis